MRT-6160
Small Molecule Target: VAV1
- Undisclosed indication
Monte Rosa Therapeutics
Most recent annual filing: 2026-03-17
- next-generation NEK7 MGD and CCNE12026next-generation NEK7 MGD and CCNE1, 2026, notable
- MRT-6160 Ph2 start2026MRT-6160 Ph2 start, 2026, routine
- MRT-8102 Ph1 interim2H 2026MRT-8102 Ph1 interim, 2H 2026, material
- MRT-2359 Ph2 start3Q 2026MRT-2359 Ph2 start, 3Q 2026, notable
- MRT-8102 GFORCE-2 Ph2 start4Q 2026MRT-8102 GFORCE-2 Ph2 start, 4Q 2026, notable
- MRT-8102 GFORCE-3 Ph2 start4Q 2026MRT-8102 GFORCE-3 Ph2 start, 4Q 2026, notable
- CCNE1 MGD IND filing2027CCNE1 MGD IND filing, 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
MRT-8102
Small Molecule Target: NEK7
MRT-2359
Small Molecule Target: GSPT1
CDK2 molecular glue degrader
Small Molecule Target: CDK2
Technology platforms
QuEEN
Quantitative and Engineered Elimination of Neosubstrates — AI/ML-enabled, target-centric molecular glue degrader discovery engine combining geometric deep learning for protein surface characterization, high-throughput screening, structural biology, and proprietary MGD library of 75,000+ compounds. Focused on immunology, inflammation, cardiovascular, oncology, and CNS diseases.
Roche Collaboration Platform · Roche
Strategic collaboration with Roche to identify and develop MGDs against cancer and neurological disease targets using Monte Rosa's QuEEN discovery platform. Monte Rosa leads preclinical discovery; Roche gains exclusive rights for further development upon defined handoff criteria.
Novartis I&I Collaboration Platform · Novartis
Collaboration, option, and license agreement with Novartis for discovery and development of degraders targeting immunology and inflammation programs. Monte Rosa applies QuEEN engine for one licensed I&I program and two optioned preclinical I&I programs; Novartis responsible for development and commercialization.
QuEEN · Novartis
AI/ML-enabled QuEEN engine for the discovery and development of molecular glue degraders (MGDs); focus areas include immunology and inflammation
Biotech Distilled coverage (2)
- 2026-08-07 UPDATE: Monte Rosa Therapeutics (GLUE) - Novartis Pushes the Button 🔒 Paid
- 2026-04-14 Monte Rosa Therapeutics (GLUE) - Scientific Deep Dive for MRT-2359, MRT-8102, and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.